Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA)
- PMID: 31353412
- DOI: 10.1093/europace/euz163
Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA)
Erratum in
-
Corrigendum to: Kalarus Z, et al. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA).Europace. 2019 Oct 1;21(10):1604. doi: 10.1093/europace/euz267. Europace. 2019. PMID: 31545378 No abstract available.
Abstract
Despite major therapeutic advances over the last decades, complex supraventricular and ventricular arrhythmias (VAs), particularly in the emergency setting or during revascularization for acute myocardial infarction (AMI), remain an important clinical problem. Although the incidence of VAs has declined in the hospital phase of acute coronary syndromes (ACS), mainly due to prompt revascularization and optimal medical therapy, still up to 6% patients with ACS develop ventricular tachycardia and/or ventricular fibrillation within the first hours of ACS symptoms. Despite sustained VAs being perceived predictors of worse in-hospital outcomes, specific associations between the type of VAs, arrhythmia timing, applied treatment strategies and long-term prognosis in AMI are vague. Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia that may be asymptomatic and/or may be associated with rapid haemodynamic deterioration requiring immediate treatment. It is estimated that over 20% AMI patients may have a history of AF, whereas the new-onset arrhythmia may occur in 5% patients with ST elevation myocardial infarction. Importantly, patients who were treated with primary percutaneous coronary intervention for AMI and developed AF have higher rates of adverse events and mortality compared with subjects free of arrhythmia. The scope of this position document is to cover the clinical implications and pharmacological/non-pharmacological management of arrhythmias in emergency presentations and during revascularization. Current evidence for clinical relevance of specific types of VAs complicating AMI in relation to arrhythmia timing has been discussed.
Keywords: Acute myocardial infarction; Atrial fibrillation; Reperfusion; Ventricular fibrillation; Ventricular tachycardia.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document contradicts current guideline recommendations.Europace. 2020 Sep 1;22(9):1442. doi: 10.1093/europace/euaa043. Europace. 2020. PMID: 32142109 No abstract available.
-
Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease.Europace. 2020 Oct 1;22(10):1600. doi: 10.1093/europace/euaa045. Europace. 2020. PMID: 32163138 No abstract available.
-
Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations-Authors' reply.Europace. 2020 Sep 1;22(9):1442-1443. doi: 10.1093/europace/euaa053. Europace. 2020. PMID: 32219381 No abstract available.
-
Defibrillators for prevention from sudden cardiac death: is it that easy?Europace. 2020 Aug 1;22(8):1298. doi: 10.1093/europace/euaa044. Europace. 2020. PMID: 32236539 Free PMC article. No abstract available.
-
Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors' reply.Europace. 2020 Oct 1;22(10):1600-1601. doi: 10.1093/europace/euaa052. Europace. 2020. PMID: 32236547 No abstract available.
-
Defibrillators for prevention from sudden cardiac death: is it that easy?-Authors' reply.Europace. 2020 Aug 1;22(8):1298-1299. doi: 10.1093/europace/euaa058. Europace. 2020. PMID: 32236556 No abstract available.
-
The wearable cardioverter-defibrillator in acute coronary syndromes, a distinctive point of view.Europace. 2020 Aug 1;22(8):1299-1300. doi: 10.1093/europace/euaa091. Europace. 2020. PMID: 32357205 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
